Priya Subramaniam

Platform architecture, not publication count, reveals whether a nanoparticle system can scale.

Nanoparticles deliver peptides across the blood-brain barrier through the nose.

Engineers are finding multiple routes to get large drug molecules into the brain.

Skin's lipid barrier makes GLP-1 patches fundamentally harder than injection, and the data prove it.

COVID-19 vaccines sparked a patent race that reshaped nanoparticle drug delivery.

Nasal delivery bypasses the blood-brain barrier for peptides that can't cross it systemically.

The handheld auto-injector hits its limits with larger, thicker drugs.

Targeting the brainstem can reduce nausea without sacrificing GLP-1's metabolic benefits.